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1. Introduction 
At the neuromuscular junction and the electro- 
motor synapse, a series of compounds referred to as 
noncompetitive blockers, inhibit the permeability 
response licited by acetylcholine (ACh) in a non- 
competitive manner (reviews [1,2]). They include, 
among others, the aminated local anesthetics proadifen 
and dimethisoquin [3-7], the frog toxin histrionico- 
toxin (HTX) and its derivatives [8-11 ], the halluci- 
nogenic drug phencyclidine [12-14]. These pharma- 
cological agents block the physiological response in 
the/~M range and their binding to saturable sites on 
ACh-receptor-rich membrane fragments i olated from 
Torpedo electric organ has been demonstrated with 
the radiolabelled derivatives [3H]meproadifen [6], 
[3H] trimethisoquin [ 15 ], [all] perhydro-HTX [ 11, 
16-18] and [3H]phencyclidine [12,19,20]. A num- 
ber of structurally unrelated compounds usually con- 
sidered as primarily interacting with the lipid phase 
of the membrane, such as the detergents Triton X-100 
or Na-cholate [21,22], fatty acids [21,36], phospho- 
lipases (reviews [23,27]), general anesthetics and 
alcohols [7,24[ also block the response to ACh in a 
noncompetitive manner. All of them regulate the 
affinity of the ACh binding site in an 'aUosteric' man- 
Abbreviations: ACh, acetylcholine; HTX, histrionicotoxin; 
Dns-C~-Cho, (1-(5-dimethylaminonaphthalene) sulfonamido) 
n-hexanoic a id 13-(N-trimethylammonium bro ide) ethyl 
ester 
ner and stabilize, to various extents, the high affinity 
'desensitized' state of the ACh-receptor, even in the 
absence of agonist [5,7]. Additive effects between the 
detergent Na-cholate and the aminated local anesthetic 
trimethisoquin [25] as well as between the alcohol 
2-propanol and perhydro-HTX [7] have been demon- 
strated and it was thus suggested that the noncompet- 
itive blockers might exert heir effect via two distinct 
modes of interaction: 
(i) They might bind to the saturable high affinity 
sites identified on the ACh-receptor-rich mem- 
branes; 
(ii) They might change, in a non-specific manner, the 
physical properties of the lipid bilayer surround- 
ing the membrane-bound ACh-receptor. 
Here, we show that the effects of membrane per- 
turbers uch as Triton X-100 or Nonidet P40, at con- 
centrations up to their critical micellar concentrations, 
can be antagonized by the potent noncompetitive 
blocker perhydro-HTX, and conversely, that the 
effects of several local anesthetics among which the 
aminated local anesthetics dimethisoquin and its 
quaternary derivative trimethisoquin are insensitive 
to perhydro-HTX. These data suggest hat: 
(i) Noncompetitive blockers, in general, may stabil- 
ize the high affinity state of the ACh-receptor 
primarily upon binding to saturable sites; 
(ii) There should exist at least two classes of such 
binding sites with distinct pharmacological 
selectivity at the level of the ACh-receptor. 
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2. Materials and methods 
2.1. Preparation of A Ch-receptor-rich membrane 
fragments 
ACh-receptor-rich membrane fragments were puri- 
fied from the electric organ of Torpedo marmorata as 
in [26] with modifications to limit proteolysis as in 
[27], and were kept in liquid nitrogen until use. ACh- 
receptor sites were quantitated by column filtration 
as in [26], using a2SI-labelled a-bungarotoxin. 
2.2. Rapid kinetics of Dns-C6-Cho binding 
The fractional concentration of receptors in the 
high affinity 'desensitized' state was determined 
by fast kinetic analysis of the binding of the fluores- 
cent cholinergic agonist Dns-C6-Cho, as in [5,28-30].  
Membrane fragments were diluted to a final concen- 
tration of ~0.1 -0 .2 / iM  a-toxin binding sites in a 
Torpedo physiological solution supplemented or not 
with given concentrations of noncompetitive blockers, 
and were rapidly mixed with a solution o f Dns-C6-Cho 
in the same medium in a Durrum stopped-flow appa- 
ratus equipped for fluorescence detection. The frac- 
tional amplitude of the relaxation process relative to 
the binding of Dns-C6-Cho to the high affinity 'desen- 
sitized' receptor sites (the 'rapid' relaxation process, 
see [5,28,29]) was determined by a non-linear iterative 
regression analysis as in [29]. 
2.3. Chemicals 
Dns-C6Cho [31,32], trimethisoquin and mepro- 
adifen were a gift from G. Waksman who synthetized 
them. Perhydro-HTX was a gift from Professor J. 
Daly. Prilocaine, lidocaine and dimethisoquin were a 
gift from the Laboratoire Roger Bellon (France), and 
proadifen agift from Smith, Kline and French. Nonidet 
P40 was from BDH Chemicals Ltd., dibucaine from 
K and K Labs. and Triton X-100, Lubrol PX and 
chlorpromazine from Sigma. 
3. Results 
As illustrated in fig.1 and extensively described in 
[5,28-30],  rapid mixing of ACh-receptor-rich mem- 
branes with the fluorescent cholinergic agonist Dns- 
C6-Cho results in an increase of fluorescence !ntensity 
which develops in the millisecond to second time 
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Fig.1. Single-shot traces of stopped-flow experiments: effect of noncompetitive blockers, kex = 290 nm, hem > 540 nm (see 
[ 29]); 1:1 mixing of a suspension of ACh-receptor rich membrane fragments (0.2/aM c~-toxin sites) in Torpedo saline solution 
(250 mM NaCI, 5 mM KC1, 4 mM CaC12, 2 mM MgC12, 5 mM sodium phosphate (pH 7)) supplemented or not with given concen- 
trations of noncompetitive blockers with a solution of Dns-C~-Cho (3/sM) in the same medium: (a) control; (b) 12/aM proadifen; 
(c) 20/aM dimethisoquin; (d) 10/aM perhydro-HTX; (e) 10/aM perhydro-HTX +12/aM proadifen; (f) 10/aM perhydro-HTX +
20/aM dimethisoquin; 'rapid' relaxation processes are represented onexpanded time scales. 
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Fig.2. Stabilization of the high affinity state of the receptor by noncompetitive blockers and differential effects of perhydro- 
HTX. Ordinates: fraction of ACh-receptor sites in the high affinity 'desensitized' state following preincubation with proadifen, 
dimethisoquin, Triton X-100 and Lubrol PX, in the absence (o) or presence (o) of 10/~M perhydro-HTX, as a function of the 
concentration f these noncompetitive blockers. The dotted lines ( - - - )  are the theoretical values, assuming aunique site of 
action for noncompetitive blockers, and calculated according to eq. (1) (see text) with a Kd-value for perhydro-HTX equal to 
0.3/~M ([ 16], unpublished). The fraction of ACh-receptor sites in the high affinity state was determined from the fractional 
amplitude of the 'rapid' relaxation process (see text and [5,29]) and experimental conditions are the same as in fig.1. 
range, according to, at least, 3 distinct processes: 
rapid, intermediate and slow. At saturating concentra- 
tion of agonist, the relative amplitude of the 'rapid' 
relaxation process (represented with an expanded 
time scale in fig.l) can be taken as an index of the 
fraction of ACh-receptor sites which exist, prior to 
agonist addition, in a high affinity 'desensitized' state 
and bind the agonist following a rapid and diffusion- 
controlled reaction [29]. According to this criterion, 
in the native membranes under resting conditions (see 
fig. 1 a), ~20% o f the receptor sites are in a high affinity 
state, in reversible quilibrium with the remaining 
80% of sites, of lower affinity, which account for the 
physiological response. 
Preincubation of the ACh-receptor-rich membrane 
fragments with noncompetitive blockers uch as pro- 
adifen or dimethisoquin (fig.1 b,c) results in an increase 
of the amplitude of the rapid relaxation process 
monitored upon mixing with Dns-C6-Cho. These non- 
competitive blockers, thus shift the equilibrium 
between the low and high affinity states of the ACh- 
receptor towards the high affinity state (see [5] for a 
detailed analysis). Quantitation of this effect (see 
fig.2) yields values for half-maximum effect, in the 
3-30/aM range for proadifen, dimethisoquin, Triton 
X-100 and Lubrol PX. Values of maximum effect are 
close to unity for the 4 noncompetitive blockers of 
fig.2, but can be smaller for instance in the case of 
Na-cholate [25], phospholipasic toxins [5], HTX [5], 
and also, as illustrated in f ig. ld (see also [7]), in the 
case of its hydrogenated derivative perhydro-HTX. 
Preincubation of the ACh-receptor-rich membrane 
fragments with perhydro-HTX at concentrations a
high as 10/aM (i.e. ~50-times its equilibrium dissocia- 
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tion constant, see [16,17]) results only in a limited 
increase of the amplitude of the rapid relaxation pro- 
cess (from 21- +2%-33-  + 2%). This limited effect, 
which can simply be accounted for by assuming that 
perhydro-HTX non-exclusively binds (see [33]) to 
both the resting and desensitized states (see [5] for a 
theoretical treatment in the case of HTX) renders 
possible a quantitative analysis of the effect of non- 
competitive blockers under conditions of perhydro- 
HTX site occupancy. 
Membrane fragments were therefore preincubated 
with a saturating concentration of perhydro-HTX 
(10/IM, see fig. 1 d - f )  supplemented with increasing 
concentrations of noncompetitive blockers. In these 
conditions, two classes of effects were observed: 
(i) With some noncompetitive blockers such as 
dimethisoquin or the detergent Lubrol PX, the 
stabilization of the high affinity state was not 
affected by perhydro-HTX; in particular, as 
shown in fig.2, the values for half-maximum 
stabilization by the noncompetitive blockers 
tested did not change. 
(ii) On the contrary, with others, such as proadifen 
but also the detergent Triton X-100, perhydro- 
HTX almost completely abolished the stabiliza- 
tion of the high affinity state (see fig.le,2). 
A variety of noncompetitive blockers were tested by 
this method and are listed in fig.3. Compounds which 
possess the structure of aminated local anesthetics or 
compounds known as detergents may exert anyone of 
the two classes of effects. 
Assuming that the allosteric regulation of the ACh- 
receptor by a noncompetitive blocker is mediated via 
a unique class of sites, the presence of perhydro-HTX 
should result in a shift of the dose-response curves 
for stabilization of the high affinity state (fig.2) 
toward the high concentration range, with values for 
half-maximum stabilization, Kap p equal to: 
Kap p = Ka°pp (1 + (H,z HTX)/Kd) (z) 
CH 
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Fig.3. Pharmacology of the two classes of noncompetitive blockers. Noncompetitive blockers were tested as in fig, l,2. They fall 
into two groups: (1) dimethisoquin and noncompetitive blockers whose effects are insensitive to perhydro-HTX; (2) proafiden 
and noncompetitive blockers whose effect are blocked by perhydro-HTX. 
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where K d is the equilibrium dissociation constant for 
the binding of perhydro-HTX, and Kap p°  the value for 
half-maximum stabilization i  the absence of perhy- 
dro-HTX. Accordingly, Kap p should be ~50-times 
higher than K°pp. Clearly, this is not the case for 
dimethisoquin a d homologues, whereas for proadifen, 
Triton X-100 and homologues such an interpretation 
appears plausible (fig.2, dotted line). 
4. Discussion 
These data disclose that several local anesthetics 
such as di- and trimethisoquin, lidocaine and prilocaine, 
stabilize the high affinity state of the ACh-receptor in
a manner which is insensitive to perhydro-HTX. On 
the other hand, several membrane perturbers, uch as 
the detergents Triton X-100 or Nonidet P40 at levels 
up to their critical micellar concentrations, exert simi- 
lar effects that perhydro-HTX blocks. A plausible 
interpretation f these data, then, is that at least two 
classes of saturable binding sites for non-competitive 
blockers, 'perhydro-HTX-sensitive' and'perhydro- 
HTX-insensitive', exist on the membrane bound ACh- 
receptor and that both typical ocal anesthetics and 
general membrane perturbers differentially interact 
with these sites. In their low concentration range, 
dimethisoquin, lidocaine, Lubrol PX and homologues 
(fig.3) would stabilize the high affinity state of the 
ACh-receptor upon binding to the perhydro-HTX- 
insensitive sites, whereas proadifen, Triton X-100 and 
homologues (fig.3) would exert their action at the 
level of the perhydro-HTX-sensitive ones. These data, 
of course, do not exclude that effectors from one 
class interact with the alternate class of sites, either 
in a non-exclusive manner or/and in a distinct concen- 
tration range. Perhydro-HTX itself might bind to the 
sites where dimethisoquin and homologues primarily 
exert their action but, in a higher concentration range. 
This interpretation is compatible with the observed 
displacement of radiolabelled aminated local anes- 
thetics and perhydro-HTX by detergents below their 
critical micellar concentration [7,15]. It might 
account for the heterogeneity of binding reported for 
[3H] trimethisoquin with ACh-receptor-rich membrane 
fragments, and for the differential effects of HTX on 
this binding [15]. It could also explain the results 
obtained upon covalent labelling by UV irradiation of 
the polypeptide chains of the ACh-receptor protein 
with radioactive noncompetitive blockers [34]. With 
all of them, the 6 chain (66 000 Mr) was found to be 
primarily labelled but with some noncompetitive 
blockers uch as [3H]chlorpromazine, other chains 
were also found radioactive, a result compatible with 
the occurrence of more than one category of binding 
sites for these effectors on the ACh-receptor protein. 
An attractive hypothesis would be that each of the 
4 ACh-receptor polypeptide chains, which exhibit 
important sequence homologies [35], carries a site 
to which the noncompetitive blockers would bind 
with distinct affinities and selectivities. Following 
this scheme, one may consider the possibility that 
these sites are in fact homologous tothe ACh-receptor 
site carried by the a-chain, and even contribute to 
the physiological response upon binding ACh in a 
high concentration range. Binding studies with radio- 
labelled noncompetitive blockers are further developed 
to identify and characterize these sites, to determine 
their stoichiometry, and to understand their physio- 
logical significance. 
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